Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape

Immunological Reviews

Volumn 222, Issue 1, 2008, Pages 206-221

  Katz, Jessica B ^a,b   Muller, Alexander J ^a,c   Prendergast, George C ^a,c,d  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b LANKENAU HOSPITAL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cancer; Dendritic cells; Signal transduction; Tolerance; Tumor immunity

Indexed keywords

1 METHYL TRYPTOPHAN; [N (3,4 DIMETHOXYCINNAMOYL)ANTHRANILIC ACID]; ABATACEPT; ACETYLSALICYLIC ACID; ANTHRANILIC ACID; BINDING PROTEIN; CD28 ANTIGEN; CYTOTOXIC AGENT; DEXTRO 1 METHYL TRYPTOPHAN; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 2; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INDOMETACIN; METHYLTHIOHYDANTOIN TRYPTOPHAN; OXYGENASE; PHENYLBUTAZONE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN INDO; PROTEIN KINASE B INHIBITOR; RAG2 PROTEIN; STAT1 PROTEIN; TRYPTOPHAN 2,3 DIOXYGENASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BLADDER CANCER; BREAST CANCER; CANCER RISK; COLON CANCER; COLORECTAL CANCER; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME DEGRADATION; GENITAL TRACT CANCER; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; KAPOSI SARCOMA; LEUKEMIA; LIVER CELL CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION;

ANIMALS; ANTIGEN PRESENTATION; CLINICAL TRIALS, PHASE I AS TOPIC; DENDRITIC CELLS; ENZYME INDUCTION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MICE; NEOPLASMS; T-LYMPHOCYTES; TRYPTOPHAN; TUMOR ESCAPE;

EID: 41149132390     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00610.x     Document Type: Review

References (136)

1. Burnet M. Cancer: a biologic approach. Br Med J 1957 1 : 841 847.
2. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006 6 : 836 848.
3. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004 21 : 137 148.
4. Gasser S, Raulet DH. The DNA damage response arouses the immune system. Cancer Res 2006 66 : 3959 3962.
5. MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003 348 : 567 568.
6. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971 28 : 89 98.
7. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007 67 : 1167 1198.
8. Penn I. Posttransplant malignancies. Transplant Proc 1999 31 : 1260 1262.
9. Brown MR, Noffsinger A, First MR, Penn I, Husseinzadeh N. HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients. Gynecol Oncol 2000 79 : 220 224.
10. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000 23 : 101 113.
11. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000 7 : 147 156.
12. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998 147 158.
13. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997 64 : 669 673.
14. Penn I. Skin disorders in organ transplant recipients. External anogenital lesions. Arch Dermatol 1997 133 : 221 223.
15. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005 5 : 263 274.
16. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005 7 : 211 217.
17. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006 66 : 5527 5536.
18. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006 6 : 613 625.
19. Munn DH, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998 281 : 1191 1193.
20. Thomas SM, et al. IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth. J Immunol 1993 150 : 5529 5534.
21. Fujigaki S, et al. l-tryptophan-l-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase. Infect Immunol 2002 70 : 779 786.
22. Hansen AM, Ball HJ, Mitchell AJ, Miu J, Takikawa O, Hunt NH. Increased expression of indoleamine 2,3-dioxygenase in murine malaria infection is predominantly localised to the vascular endothelium. Int J Parasitol 2004 34 : 1309 1319.
23. Larrea E, et al. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol 2007 81 : 3662 3666.
24. Boyland E, Williams DC. The estimation of tryptophan metabolites in the urine of patients with cancer of the bladder. Process Biochem 1955 60 : v.
25. Ambanelli U, Rubino A. Some aspects of tryptophan-nicotinic acid chain in Hodgkin's disease. Relative roles of tryptophan loading and vitamin supplementation on urinary excretion of metabolites. Haematol Lat 1962 5 : 49 73.
26. Ivanova VD. Disorders of Tryptophan Metabolism in Leukaemia. Acta Unio Int Contra Cancrum 1964 20 : 1085 1086.
27. Rose DP. Tryptophan metabolism in carcinoma of the breast. Lancet 1967 1 : 239 241.
28. Wolf H, Madsen PO, Price JM. Studies on the metabolism of tryptophan in patients with benign prostatic hypertrophy or cancer of the prostate. J Urol 1968 100 : 537 543.
29. Hayaishi O, Ryotaro Y, Takikawa O, Yasui H. Indoleamine-dioxygenase - a possible biological function. Progress in Tryptophan and Seratonin Research. Berlin : Walter De Gruyter and Co. 1984 : 33 42.
30. Higuchi K, Hayaishi O. Enzymic formation of d-kynurenine from d-tryptophan. Arch Biochem Biophys 1967 120 : 397 403.
31. Higuchi K, Kuno S, Hayaishi O. Enzymatic formation of D-kynurenine. Federation Proc 1963 22 : 243 (abstr.).
32. Shimizu T, Nomiyama S, Hirata F, Hayaishi O. Indoleamine 2,3-dioxygenase. Purification and some properties. J Biol Chem 1978 253 : 4700 4706.
33. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991 5 : 2516 2522.
34. Watanabe Y, Yoshida R, Sono M, Hayaishi O. Immunohistochemical localization of indoleamine 2,3-dioxygenase in the argyrophilic cells of rabbit duodenum and thyroid gland. J Histochem Cytochem 1981 29 : 623 632.
35. Sugimoto H, Oda SI, Otsuki T, Hino T, Yoshida T, Shiro Y. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 2006 103 : 2611 2616.
36. Sono M. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 2. Evidence for the existence of another binding site in the enzyme for indole derivative effectors. Biochemistry 1989 28 : 5400 5407.
37. Kadoya A, Tone S, Maeda H, Minatogawa Y, Kido R. Gene structure of human indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 1992 189 : 530 536.
38. Najfeld V, Menninger J, Muhleman D, Comings DE, Gupta SL. Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12->p11 by fluorescent in situ hybridization. Cytogenet Cell Genet 1993 64 : 231 232.
39. Arefayene M, et al. Identification of functional genetic variants of the indoleamine 2, 3 dioxygenase gene. American Association for Cancer Research 97th Annual Meeting Proceedings; 2006 Apr 1-5, Washington, DC: 1119.
40. Okamoto A, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005 11 : 6030 6039.
41. Brandacher G, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006 12 : 1144 1151.
42. Wolf AM, et al. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol 2004 113 : 47 55.
43. Nakamura T, et al. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007 98 : 874 881.
44. Astigiano S, et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 2005 7 : 390 396.
45. Lee JR, et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003 83 : 1457 1466.
46. Munn DH, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004 114 : 280 290.
47. Alvaro T, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005 11 : 1467 1473.
48. Badoual C, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006 12 : 465 472.
49. Ishio T, Goto S, Tahara K, Tone S, Kawano K, Kitano S. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004 19 : 319 326.
50. Ball HJ, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007 396 : 203 213.
51. Murray MF. The human indoleamine 2,3-dioxygenase gene and related human genes. Curr Drug Metab 2007 8 : 197 200.
52. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the anti-tumor indoleamine 2,3-dioxygenase inhibitory compound d-1-methyl-tryptophan. Cancer Res 2007 67 : 7082 7087.
53. Muller AJ, Metz R, Prendergast GC. Differential targeting of tryptophan catabolism in tumors and in tumor-draining lymph nodes by stereoisomers of the IDO inhibitor 1-methyl-tryptophan. Int Congr Ser 2008 1304C : 250 261.
54. Munn DH, et al. GCN2 kinase in T cells mediates proliferative arrest and energy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005 22 : 633 642.
55. Yasui H, Takai K, Yoshida R, Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurence in cancer patients. Proc Natl Acad Sci USA 1986 83 : 6622 6626.
56. Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2,3-dioxygenase: a mechanism of the anti-tumor activity of interferon gamma. Proc Natl Acad Sci USA 2008 85 : 1242 1246.
57. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999 20 : 469 473.
58. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999 189 : 1363 1372.
59. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003 24 : 242 248.
60. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004 10 : 15 18.
61. Platten M, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005 310 : 850 855.
62. Zhu L, et al. Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J Immunol 2006 177 : 8226 8233.
63. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and trytophan catabolism. Nat Rev Immunol 2004 4 : 762 774.
64. Carlin JM, Borden EC, Sondel PM, Byrne GI. Biologic-response-modifier- induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol 1987 139 : 2414 2418.
65. Carlin JM, Borden EC, Sondel PM, Byrne GI. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol 1989 45 : 29 34.
66. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000 164 : 3596 3599.
67. Takikawa O, Tagawa Y, Iwakura Y, Yoshida R, Truscott RJ. Interferon-gamma-dependent/independent expression of indoleamine 2,3-dioxygenase. Studies with interferon-gamma-knockout mice. Adv Exp Med Biol 1999 467 : 553 557.
68. Du MX, Sotero-Esteva WD, Taylor MW. Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-gamma. J Interferon Cytokine Res 2000 20 : 133 142.
69. Chon SY, Hassanain HH, Gupta SL. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma- inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996 271 : 17247 17252.
70. Chon SY, Hassanain HH, Pine R, Gupta SL. Involvement of two regulatory elements in interferon-gamma-regulated expression of human indoleamine 2,3-dioxygenase gene. J Interferon Cytokine Res 1995 15 : 517 526.
71. Konan KV, Taylor MW. Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996 271 : 19140 19145.
72. Robinson CM, Hale PT, Carlin JM. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 2005 25 : 20 30.
73. Pine R. Convergence of TNFalpha and IFNgamma signalling pathways through synergistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/kappaB promoter element. Nucleic Acids Res 1997 25 : 4346 4354.
74. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005 106 : 2375 2381.
75. Wobser M, et al. Dendritic cell based anti-tumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol Immunother 2007 56 : 1017 1024.
76. Sayama S, Yoshida R, Oku T, Imanishi J, Kishida T, Hayaishi O. Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. Proc Natl Acad Sci USA 1981 78 : 7327 7330.
77. Marshall B, Keskin DB, Mellor AL. Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme. BMC Biochem 2001 2 : 5.
78. Chiarugi A, Rovida E, Dello Sbarba P, Moroni F. Tryptophan availability selectively limits NO-synthase induction in macrophages. J Leukoc Biol 2003 73 : 172 177.
79. Alberati-Giani D, Malherbe P, Ricciardi-Castagnoli P, Kohler C, Denis-Donini S, Cesura AM. Differential regulation of indoleamine 2,3-dioxygenase expression by nitric oxide and inflammatory mediators in IFN-gamma-activated murine macrophages and microglial cells. J Immunol 1997 159 : 419 426.
80. Daubener W, Posdziech V, Hadding U, MacKenzie CR. Inducible anti-parasitic effector mechanisms in human uroepithelial cells: tryptophan degradation vs. NO production. Med Microbiol Immunol (Berlin) 1999 187 : 143 147.
81. Thomas SR, Mohr D, Stocker R. Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. J Biol Chem 1994 269 : 14457 14464.
82. Hucke C, MacKenzie CR, Adjogble KD, Takikawa O, Daubener W. Nitric oxide-mediated regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human indoleamine 2,3-dioxygenase. Infect Immunol 2004 72 : 2723 2730.
83. Samelson-Jones BJ, Yeh SR. Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry 2006 45 : 8527 8538.
84. Fallarino F, et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 2004 200 : 1051 1062.
85. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res 2006 66 : 3963 3966.
86. Yuan W, Collado-Hidalgo A, Yufit T, Taylor M, Varga J. Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-beta: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J Cell Physiol 1998 177 : 174 186.
87. Moser M. Dendritic cells in immunity and tolerance-do they display opposite functions? Immunity 2003 19 : 5 8.
88. Ghiringhelli F, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005 202 : 919 929.
89. Liu Y, Bi X, Xu S, Xiang J. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses. Cancer Res 2005 65 : 4955 4962.
90. Salomon B, et al. B7/CD28 constimulation is essential for the homeostasis of the CD41CD251 immunoregulatory T cells that control autoimmune diabetes. Immunity 2000 12 : 431 440.
91. Lohr J, Knoechel B, Jiang S, Sharpe AH, Abbas AK. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol 2003 4 : 664 669.
92. Lohr J, Knoechel B, Kahn EC, Abbas AK. Role of B7 in T cell tolerance. J Immunol 2004 173 : 5028 5035.
93. Liang S, Alard P, Zhao Y, Parnell S, Clark SL, Kosiewicz MM. Conversion of CD41CD25 cells into CD41CD251 regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med 2005 201 : 127 137.
94. Mellor AL, et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003 171 : 1652 1655.
95. Mellor AL, et al. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004 16 : 1391 1401.
96. Fallarino F, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003 4 : 1206 1212.
97. Grohmann U, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002 3 : 1097 1101.
98. Munn DH, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002 297 : 1867 1870.
99. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003 3 : 253 257.
100. Piccirillo CA, Shevach EM. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 2004 16 : 81 88.
101. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004 22 : 531 562.
102. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003 3 : 199 210.
103. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004 5 : 266 271.
104. Zenclussen AC, et al. Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol 2005 166 : 811 822.
105. Rouse BT, Suvas S. Regulatory T cells and immunity to pathogens. Expert Opin Biol Ther 2007 7 : 1301 1309.
106. Boettler T, et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005 79 : 7860 7867.
107. Andersson J, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol 2005 174 : 3143 3147.
108. Hryniewicz A, et al. CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 2006 108 : 3834 3842.
109. Mellor AL, Munn DH. Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003 170 : 5809 5813.
110. Terness P, Chuang JJ, Opelz G. The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol 2006 27 : 68 73.
111. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002 2 : 116 126.
112. Karandikar NJ, Vanderlugt CL, Bluestone JA, Miller SD. Targeting the B7/CD28: CTLA-4 costimulatory system in CNS autoimmune disease. J Neuroimmunol 1998 89 : 10 18.
113. Grohmann U, et al. IL-12 acts selectively on CD8 alpha- dendritic cells to enhance presentation of a tumor peptide in vivo. J Immunol 1999 163 : 3100 3105.
114. Grohmann U, et al. IFN-gamma inhibits presentation of a tumor/self peptide by CD8 alpha dendritic cells via potentiation of the CD8 alpha+ subset. J Immunol 2000 165 : 1357 1363.
115. Fallarino F, et al. Functional expression of indoleamine 2, 3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol 2002 14 : 65 68.
116. Grohmann U, et al. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol 2001 166 : 277 283.
117. Grohmann U, et al. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J Immunol 2003 171 : 2581 2587.
118. Orabona C, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004 5 : 1134 1142.
119. Orabona C, et al. Towards the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 2006 107 : 2848 2854.
120. Orabona C, et al. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol 2005 174 : 6582 6586.
121. Orabona C, et al. Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. Eur J Immunol 2005 35 : 3111 3118.
122. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002 23 : 549 555.
123. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005 174 : 636 645.
124. Hwang SL, Chung NP, Chan JK, Lin CL. Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines. Cell Res 2005 15 : 167 175.
125. Fallarino F, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002 9 : 1069 1077.
126. Muller AJ, Malachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 2005 9 : 831 849.
127. Fallarino F, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006 176 : 6752 6761.
128. Friberg M, et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 2002 101 : 151 155.
129. Uyttenhove C, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003 9 : 1269 1274.
130. Muller AJ, Duhadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005 11 : 312 319.
131. Hou DY, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with anti-tumor responses. Cancer Res 2007 67 : 792 801.
132. Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 2004 61 : 67 77.
133. Gaspari P, et al. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem 2006 49 : 684 692.
134. Banerjee T, et al. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene advance online publication 2007; (DOI).
135. Park EJ, Pezzuto JM. Botanicals in cancer chemoprevention. Cancer Metastasis Rev 2002 21 : 231 255.
136. Mehta RG, et al. Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. Carcinogenesis 1995 16 : 399 404.